Collagen-hydroxyapatite/cisplatin drug delivery systems for locoregional treatment of bone cancer

Technol Cancer Res Treat. 2013 Aug;12(4):275-84. doi: 10.7785/tcrt.2012.500331. Epub 2013 Mar 26.

Abstract

In this paper, the synthesis and characterization of novel cisplatin-loaded collagen (COLL)/hydroxyapatite (HA) composite materials are presented. The composite materials were designed to obtain a COLL: HA weight ratio close to the bone composition. The content of embedded cisplatin was chosen to assure a concentration of cisplatin of 6 and 10 μM, respectively, into the culture media used in cell culture experiments. These cisplatin delivery systems were characterized by determining the physico-chemical properties of the composite material, the drug release process as well as their biological activity. Based on the in vitro data that showed the cytotoxic, anti-proliferative and anti-invasive activities of these multifunctional systems on G292 osteosarcoma cells in dependence on the cisplatin concentration released in culture medium, we conclude that the newly developed COLL/HA-cisplatin drug delivery system could be a feasible approach for locoregional chemotherapy of bone cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / pathology
  • Cell Line, Tumor
  • Cisplatin / administration & dosage*
  • Collagen / administration & dosage*
  • Drug Delivery Systems*
  • Durapatite / administration & dosage*
  • Humans
  • Porosity
  • Proliferating Cell Nuclear Antigen / analysis
  • Spectrophotometry, Infrared
  • X-Ray Diffraction

Substances

  • Antineoplastic Agents
  • Proliferating Cell Nuclear Antigen
  • Collagen
  • Durapatite
  • Cisplatin